Phase 2 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 20 to 80 years old
- People who are scheduled for surgery to remove colon or rectal cancer, with the goal of curing the cancer
- People who have a single colon or rectal cancer tumour, confirmed by a full colonoscopy and biopsy
- People who have no signs of cancer that has spread to other parts of the body before surgery, confirmed by appropriate scans
- People who are in generally good health or have only mild to moderate health limitations, as assessed by a doctor (confirm with trial site)
- People who are willing and able to follow all study procedures, both physically and mentally
- People who have signed a consent form agreeing to take part
Who may not be able to join:
- People whose cancer has already spread to other parts of the body before surgery
- People whose surgery is not intended to cure the cancer
- People with kidney problems, shown by a blood test result above a certain level
- People with serious heart failure (a significant reduction in the heart's ability to pump properly)
- People with serious liver problems, including cirrhosis or elevated liver test results
- People who currently have asthma or a lung condition called Chronic Obstructive Pulmonary Disease (COPD)
- People who take medication to manage type 1 or type 2 diabetes
- People who have a condition affecting the blood vessels in the arms or legs (peripheral vascular disease)
- People with a known allergy to any of the medications used in this study
- People with a known allergy to anti-inflammatory medications (such as ibuprofen-type drugs) or a type of heart medication called beta-blockers
- People who regularly take beta-blocker medications or a type of anti-inflammatory medication called COX inhibitors
- People who have an abnormally slow heart rate or certain types of heart rhythm problems
- People who have had a stroke or a temporary stroke-like episode (TIA)
- People who have a specific type of chest pain caused by coronary artery spasm (Prinzmetal's angina)
- People who have right-sided heart failure caused by high blood pressure in the lungs
- People with a diagnosed condition where the heart is significantly enlarged
- People who currently have a tumour on their adrenal gland called a pheochromocytoma
- People who regularly take a heart medication called Digoxin
- People with active stomach ulcers or peptic disease
- People who are pregnant
- People who are currently taking part in another interventional clinical trial
- People who have had, or currently have, any other type of cancer (other than the current colon or rectal cancer)
- People who have received chemotherapy in the last 10 years for any reason, except for pre-surgery treatment for rectal cancer within the last six months
- People who take medications that suppress the immune system
- People with immune system disorders or autoimmune diseases treated with immune-suppressing medications
- People who have a heart condition called sick sinus syndrome
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Oded Zmora, MD, Asaf Harofeh Medical Center
Phone: +97289779202
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
5-year disease-free-survival; Biomarkers in extracted tumor tissue samples assessing pro- and anti-metastatic processes; Biomarkers in blood samples assessing pro- and anti-metastatic processes
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.